NEW YORK (GenomeWeb) – Nuclea Biotechnologies Founder and former CEO Patrick Muraca is attempting to buy the bankrupt company's assets for $330,000 after they failed to sell at auction in January.

Don Beskrone, Nuclea's Chapter 7 trustee, filed a motion in US Bankruptcy Court for the District of Delaware on March 6 requesting that the court approve the sale of Nuclea's assets to NanoMolecularDx (NMDX), the company Muraca founded as a spinoff from Nuclea in 2015 upon being replaced as Nuclea's President and CEO by Donald Pogorzelski, a former president of Genzyme Diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.